NCT00420563 2026-03-16
PAL-ANGI
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
140 trialsNCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT03752333 2026-01-22
CUPem
Imperial College London
Phase 2 Completed
NCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
NCT04819373 2025-11-12
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Eikon Therapeutics
Phase 2 Completed
NCT03652493 2025-10-06
PRO-CARBO
Centre Francois Baclesse
Phase 2 Completed
NCT03755895 2025-10-03
HYCUDES
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT06926673 2025-07-03
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
Phase 2 Completed
NCT00505063 2025-06-15
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03406650 2025-05-04
SAKK 06/17
Swiss Cancer Institute
Phase 2 Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT04014075 2025-04-03
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Daiichi Sankyo
Phase 2 Completed
NCT06083662 2025-03-18
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
Phase 2 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT05663801 2024-12-27
Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy
Beni-Suef University
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT03760081 2024-11-13
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
Astellas Pharma Inc
Phase 2 Completed
NCT04065139 2024-09-19
PIPAC EstoK 01
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT03094286 2024-06-24
Durvalumab in HIV-1 Patients With Solid Tumors
Spanish Lung Cancer Group
Phase 2 Completed
NCT04193553 2024-06-18
LENVAGIST
Centre Leon Berard
Phase 2 Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT05160051 2024-04-12
68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer
University Hospital, Essen
Phase 2 Completed
NCT04410653 2024-04-05
Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
Phase 2 Completed
NCT06238752 2024-02-02
RENMIN-213
Renmin Hospital of Wuhan University
Phase 2 Completed
NCT03891238 2024-02-01
ARIES
Consorzio Oncotech
Phase 2 Completed
NCT00755898 2023-11-30
Urinary Excretion of Acetylamantadine by Cancer Patients
University of Manitoba
Phase 2 Completed
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT04259658 2023-10-03
CAEP-B
Zealand University Hospital
Phase 2 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT01746225 2023-06-01
SNAP
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03970070 2023-05-16
Perioperative Ostomy Self-Management Telehealth for Cancer Patients and Family Caregivers
City of Hope Medical Center
Phase 2 Completed
NCT05553808 2023-01-19
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
GlaxoSmithKline
Phase 2 Completed
NCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT02463877 2022-09-14
A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy
University of California, San Diego
Phase 2 Completed
NCT01220752 2022-09-01
IMRT-HIT-SNT
Heidelberg University
Phase 2 Completed
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed
NCT01280032 2022-07-22
Kypho-IORT
Universitätsmedizin Mannheim
Phase 2 Completed
NCT02920476 2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2 Completed
NCT02832167 2022-05-09
CheckMate 627
Bristol-Myers Squibb
Phase 2 Completed
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed